Clinical Trial Update: The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing long-term antibody persistence of MenACWY-TT vaccine to licensed ACWY vaccines, including a booster at 10 years, in healthy adolescent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infection

Drugs mentioned

• MenACWY (Meningococcal conjugate vaccine A/C/W-135/Y)
• MenACWY-TT (Meningococcal ACWY tetanus toxoid conjugate vaccine)
• Mencevax

Snippet

Sponsor: Pfizer | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2019-06-07